LENZ Therapeutics, Inc. (LENZ)

The FDA approved VIZZ™ for the treatment of presbyopia on July 31, 2025. The commercial launch of VIZZ™ in the U.S. began in October 2025, with broad product availability anticipated by mid-Q4 2025. LENZ Therapeutics reported its Q3 2025 earnings on November 5, 2025, highlighting a significant increase in operating expenses and a net loss per share of $0.59. On December 12, 2025, LENZ's stock price plummeted following reports of a retinal tear associated with its VIZZ™ eye drop.

There is no specific information indicating strong demand seasonality for LENZ Therapeutics' products or services. The market for presbyopia treatment is experiencing significant growth due to the rising geriatric population, increasing screen time, and heightened awareness about treatment options, suggesting consistent underlying demand.

LENZ Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing ophthalmic pharmaceutical products to improve vision, particularly for treating presbyopia. The company operates within the Health Technology and Healthcare sectors, specifically in Pharmaceuticals: Major, Drug Discovery, and Biotechnology industries. Its flagship product is VIZZ™ (aceclidine ophthalmic solution) 1.44%, a once-daily eye drop designed to temporarily improve near vision for adults with presbyopia and the company also has product candidates LNZ100 and LNZ101 in Phase III clinical trials for presbyopia.

LENZ Therapeutics is headquartered in San Diego, California, with some sources also listing Solana Beach, CA. The company is actively commercializing VIZZ™ in the United States and is pursuing international licensing partnerships to expand global access to its product.

LENZ Therapeutics' brand reputation has been shaped by the FDA approval and commercial launch of VIZZ™, as well as a reported retinal tear associated with the eye drop. The FDA approval and commercial launch were positive developments, with the company planning a direct-to-consumer campaign. However, the reported retinal tear and ensuing legal investigation have negatively impacted the company's reputation and investor confidence.

Institutional investors hold a significant portion of LENZ Therapeutics' stock, ranging from 54.32% to 72.66%, while insiders hold between 6.90% and 15.14% of the stock. Major institutional shareholders include Ra Capital Management, L.p., Falcon Edge Capital, LP, Versant Venture Management, LLC, UBS Group AG, BlackRock, Inc., and Vanguard Group Inc. Individual insider owners include Peter Kolchinsky, Richard Gerson, Brad Bolzon, and James W. McCollum (co-founder).